Reata Pharmaceuticals — Q3 2022 Earnings Presentation
23 slides from Reata Pharmaceuticals's earnings presentation, Nov 8, 2022
Slide 1: 3rd Quarter 2022 Financial Results and Update on Development Programs
3rd Quarter 2022 Financial Results and Update on Development Programs November 8, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg
Slide 3: Today's Agenda
Today’s Agenda Opening Remarks | Warren Huff, CEO Development Update | Colin Meyer, Chief Innovation Officer Commercial Update | Dawn Bir, Chief Commercial Officer Financial & Operational Update | Manmeet Soni, President, COO & CF0 Concluding Remarks | Warren Huff, CEO
Slide 4: Omaveloxolone Program in FA Development Timeline
Omaveloxolone Program in FA Development Timeline FA: Friedreich’s ataxia, mFARS: modified Friedreich’s ataxia rating scale, NDA: New Drug Application, FDA: United States Food & Drug Administration, PDUFA: Prescription Drug User Fee Act, MAA: Marketing Authorization Application 2Q21 FDA suggests Pre-
Slide 5: Late-Cycle Meeting Agenda and Discussion
Late-Cycle Meeting Agenda and Discussion Meeting does not address the final regulatory decision for the NDA FDA stated they continue to review the analyses and data included in the recent NDA submissions No request for additional data or analyses No outstanding information requests No current plans
Slide 6: Omaveloxolone MAA Submission in Europe
Omaveloxolone MAA Submission in Europe EMA: European Medicines Agency Received a positive opinion from the Pediatric Committee on our Pediatric Investigation Plan Received EMA Follow-Up Protocol Assistance feedback regarding our nonclinical and CMC programs Agreed that certain nonclinical studies, i
Slide 7: Update on Bardoxolone Program in Chronic Kidney Disease
Update on Bardoxolone Program in Chronic Kidney Disease FALCON Phase 3 trial in patients with ADPKD is ongoing International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patients with ADPKD Primary endpoint: eGFR change from baseline at Week 108 More th
Slide 8: Omaveloxolone in Friedreich's Ataxia
Omaveloxolone in Friedreich’s Ataxia
Slide 9: MOXIe Part 2: Pivotal Trial of Omaveloxolone in FA
MOXIe Part 2: Pivotal Trial of Omaveloxolone in FA MOXIe Part 2, one of the largest completed global interventional studies in patients with FA, met mFARS primary endpoint (p=0.014) Improvement observed in all subsections relative to placebo Major subgroups and all analysis populations favored omave
Slide 10: FA Pathophysiology: Frataxin Deficiency Results in Nrf2 Suppression
FA Pathophysiology: Frataxin Deficiency Results in Nrf2 Suppression that Impairs Mitochondrial Function Doni et al. FASEB J. 2021;35:e21362; Lodi et al. Proc Natl Acad Sci U S A 1999;96:11492-11495; Drinkard et al., Arch Phys Med Rehabil. 2010;91:1044-1050, OCR: Oxygen consumption rate, FARS: Friedr
Slide 11: Mechanism of Action: mFARS Improvements Associated with Induction of Nrf2
Mechanism of Action: mFARS Improvements Associated with Induction of Nrf2 Petrillo et al. Int J Mol Sci 2019;20:5211; Reata Study Report RTA400-R-2014 Omaveloxolone restores Nrf2 activity and increases mitochondrial function in FA models and patient fibroblasts In MOXIe Part 2, omaveloxolone treatme
Slide 12: Propensity-Matched Analysis: Use of External Natural History Control Group
Propensity-Matched Analysis: Use of External Natural History Control Group Post hoc analysis comparing the mFARS progression of omaveloxolone-treated patients in MOXIe Extension propensity score-matched to untreated patients in FA-COMS, the largest natural history study of Friedreich’s ataxia Improv
Slide 13: Commercial Update
Commercial Update
Slide 14: FA Represents a Significant Commercial Opportunity
FA Represents a Significant Commercial Opportunity 1NIH Friedreich Ataxia Fact Sheet (Accessed 10/2022); 22022 FA Claims analysis; 3Rummey et al. July 2022, Neurology, DOI 10.1212/WNL.0000000000200913, HCP: Health care provider ~4,000 diagnosed U.S. patients No approved FA therapies Engaged, connect
Slide 15: Launch preparation has accelerated with regulatory progress
Launch preparation has accelerated with regulatory progress Commercial leadership team with > 25 years average experience Commercial hiring and organizational growth initiated Commercial department expected to be ready by PDUFA date Experienced Reata Commercial Team Actively Preparing for Launch Hig
Slide 16: HCPs Treating FA Patients Identified
HCPs Treating FA Patients Identified At Launch, Reata’s Sales Force will Focus on HCPs with Diagnosed Patients 12022 FA Claims analysis; 2https://curefa.org/network; 3https://www.ataxia.org/neurologists-and-specialty-clinics/ Reata Commercial team of 55-60 employees including the sales force and pay
Slide 17: Patient Access Services and HCP Support
Patient Access Services and HCP Support Commercial Copay Support Uninsured Services Therapy Adherence Insurance & Access Resource Referrals New Patient Start The Reata REACH Program: Single Point of Contact for Physicians & Patients Patient intake and new patient starts Commercial copay assistance E
Slide 18: Financial & Operational Update
Financial & Operational Update
Slide 19: Financial Summary
Financial Summary 1Excludes stock-based compensation expenses; 2Excludes various adjustments, including stock-based compensation expenses, non-cash interest expense from liability related to sale of future royalties; see the next slide for a reconciliation between GAAP and non-GAAP measures. GAAP: G
Slide 20: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 21: Concluding Remarks
Concluding Remarks
Slide 22: Reata at a Glance
Reata at a Glance NDA for omaveloxolone in FA under review with PDUFA Feb. 28, 2023 Plan to submit MAA for omaveloxolone this year Plan to pursue development of omaveloxolone in additional neurological diseases FALCON Phase 3 trial in ADPKD ongoing with more than 605 patients enrolled AYAME topline
Slide 23: Thank you
Thank you
Reata Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix